2025
Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate
Kranzler H, Jinwala Z, Davis C, Xu H, Biernacka J, Zhou H, Kember R, Gelernter J, Feinn R. Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate. Alcohol Clinical And Experimental Research 2025, 49: 1297-1305. PMID: 40445294, PMCID: PMC12173784, DOI: 10.1111/acer.70052.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderProblematic alcohol useAlcohol-related problemsPlacebo-controlled trialModerators of treatment outcomePlacebo-controlled trial of topiramateReduce heavy drinking daysTreat alcohol use disorderAlcohol-related traitsTrial of topiramateResponse to topiramateEffects of topiramateTime to relapseGenome-wide association studiesTopiramate's effectsAUD treatmentDrinking daysUse disorderTopiramate groupPolygenic riskHeavy drinkingAlcohol usePharmacogenetic approachShort IndexPilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
Ghali F, Blaha O, Lam H, Kennedy S, Wright J. Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer. Journal Of Clinical Oncology 2025, 43: 865-865. DOI: 10.1200/jco.2025.43.5_suppl.865.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerVariant allele fractionUrinary DNAIntravesical therapyBladder cancerPathogenic variantsTransurethral resection of bladder tumorMedian time to recurrenceResection of bladder tumorNext-generation sequencingDetection of recurrenceTime to recurrenceTime to relapseRecurrence of tumorBiomarkers of recurrencePilot studyTransurethral resectionBladder tumorsMedian ageRecurrenceAllele fractionUrine samplesTumorBiomarkers
2024
TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 2024, 144: 924. DOI: 10.1182/blood-2024-201526.Peer-Reviewed Original ResearchReduced intensity conditioningRelapse-free survivalPost-HCTDonor chimerismTreatment armsFollow-upControl armMalignant lineagesGrade 2-4 acute graft-versus-host diseaseT cell receptor-engineered T cellsControl subjectsIncreased relapse-free survivalGraft-versus-host diseaseMedian time to relapseControl arm subjectsNon-relapse deathPost-HCT MRDComplete donor chimerismDonor-derived cellsEngineered T cellsMedian Follow-UpTime to relapseCD3+ cellsPhase 1 studyARMS subjects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply